Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2026)
Artiva Biotherapeutics (ARTV) reported Change in Receivables of -$67000.0 for Q1 2026, down 176.14% year-over-year from $88000.0 in Q1 2025, and down 458.33% quarter-over-quarter from -$12000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Change in Receivables data on file, last reported at -$67000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$67000.0, down 176.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$234000.0 (up 65.07% YoY), and the FY2025 annual result was -$79000.0, up 86.33% from the prior year.
- Change in Receivables retreated to -$67000.0 in Q1 2026 per ARTV's latest filing, from -$12000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $180000.0 in Q1 2024 and troughed at -$888000.0 in Q4 2023.
- A 4-year average of -$153818.2 and a median of -$67000.0 in 2026 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 107.74% in 2025 and fell as far as 1600.0% in 2025.
- A 4-year view of Change in Receivables shows it stood at -$888000.0 in 2023, then jumped by 87.27% to -$113000.0 in 2024, then jumped by 89.38% to -$12000.0 in 2025, then tumbled by 458.33% to -$67000.0 in 2026.
- Business Quant data shows ARTV's Change in Receivables at -$67000.0 in Q1 2026, -$12000.0 in Q4 2025, and $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - | -67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67,000.00 |
| Mar 31, 2026 | -67,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | -204,000.00 |
| Jun 30, 2025 | -204,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | -113,000.00 |
| Dec 31, 2024 | -113,000.00 |
| Sep 30, 2024 | -633,000.00 |
| Sep 30, 2024 | -633,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | -888,000.00 |
| Dec 31, 2023 | -888,000.00 |